LL‑37 Levels Reflect Sleep Quality in Obstructive Sleep Apnea
Observational study links plasma LL‑37 levels to sleep quality in obstructive sleep apnea, suggesting pLL‑37 as a potential biomarker of disease severity and immune vulnerability.
Key Takeaways
- Plasma LL‑37 levels fall as sleep apnea severity increases.
- Lower LL‑37 associates with more Stage N1 and less deep and REM sleep.
- LL‑37 may serve as a biomarker of impaired oxygenation and sleep fragmentation in OSA.
What did the study find about plasma LL‑37 levels in patients with sleep apnea?
Researchers measured plasma LL‑37 in 58 men with OSA and 20 controls using enzyme immunoassay. Plasma LL‑37 levels (pLL‑37) were significantly lower in individuals with moderate‑to‑severe OSA (AHI ≥ 15; mean 47.1 ng/L) compared to those with AHI < 15 (mean 75.3 ng/L) (journals.plos.org). pLL‑37 correlated negatively with Apnea–Hypopnea Index, oxygen desaturation index, arousal index, and percent Stage N1 sleep, and positively with Stage N3 sleep, REM sleep, mean and minimum SpO₂ (journals.plos.org). Multiple regression identified %Stage N1 and AHI as independent predictors of pLL‑37 levels (journals.plos.org).
What might plasma LL‑37 indicate about sleep quality and immune status?
LL‑37 is an antimicrobial peptide produced by neutrophils and epithelial cells. It has broad antimicrobial and immunomodulatory functions, including pathogen defense and Toll‑like receptor signaling (journals.plos.org). Reduced pLL‑37 in OSA likely reflects impaired innate immune defense linked to intermittent hypoxia and sleep fragmentation, according to the study authors (journals.plos.org). Lower LL‑37 may signal vulnerability to infection in patients with poor sleep quality.
Did CPAP treatment restore LL‑37 levels in sleep apnea patients?
The study tracked 20 OSA patients who received nasal CPAP treatment for approximately three months. Their sleep parameters improved. Plasma LL‑37 rose from 41.8 ng/mL to 54.3 ng/mL, but that increase did not reach statistical significance (p = 0.052) (journals.plos.org). The authors note that the CPAP duration may have been too short to restore LL‑37 levels fully.
FAQ
What does plasma LL‑37 indicate in obstructive sleep apnea?
Plasma LL‑37 reflects the severity of obstructive sleep apnea and correlates with sleep fragmentation, oxygen desaturation, and reduced deep and REM sleep.
How is sleep quality linked to plasma LL‑37 levels?
Lower plasma LL‑37 associates with more Stage N1 (light sleep), higher arousal index, lower Stage N3 and REM sleep, pointing to poorer sleep quality.
Can CPAP treatment normalize plasma LL‑37?
In this study, CPAP treatment over three months trended toward raising LL‑37 levels, but the change was not statistically significant.
Is plasma LL‑37 a validated biomarker of sleep apnea?
This observational study suggests plasma LL‑37 holds promise as a biomarker of disease severity and immune vulnerability in OSA, but more research is required before clinical use.
Is plasma LL‑37 reduced in severe obstructive sleep apnea?
Yes. Individuals with AHI ≥ 15 events/h had significantly lower plasma LL‑37 concentrations compared with those with milder or no OSA.
Disclaimer: This article is for general information only and is not medical advice. Consult a licensed clinician before using any peptide product.